Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-1742600
Argon Beam Coagulation as an Adjuvant for Extended Curettage for Giant Cell Tumors of the Bone: A Study of 50 Cases
Article in several languages: português | English![](https://www.thieme-connect.de/media/10.1055-s-00042410/202302/lookinside/thumbnails/10-1055-s-0042-1742600_2100164_en-1.jpg)
Abstract
Objective Extended curettage with adjuvants of giant cell tumors of bone is associated with a lower rate of recurrence of the tumor while preserving the adjacent joint. The present study was conducted to estimate the recurrence rate and functional outcome after using argon beam as an adjuvant for extended curettage.
Methods We selected 50 patients with giant cell tumors, meeting all the inclusion criteria, who underwent extended curettage using high speed burr and argon beam photocoagulation between July 2016 to January 2019. On their follow-up visit, they were assessed for any complaints of pain and signs like tenderness, locally raised temperature, and decreased range of motion of the adjacent joint. Radiologically, the patients were assessed for any increased lucency around the cement mantle and uptake of the subarticular graft. Musculoskeletal Tumor Society Score (MSTS) was administered to the patients, and range of motion of the adjacent joint was compared with the contralateral joint.
Results Recurrence was found in 4 patients, that is, an 8% recurrence rate. Twenty-six out of 28 patients with a tumor in the lower limb had a grade-5 weight bearing status 6 months from the surgery, and their range of motion was comparable to contralateral healthy joint with an average MSTS score of 27 (18–30).
Conclusion Extended curettage of giant cell tumors using argon beam coagulation is associated with low recurrence rates of the tumor and is an effective modality in the treatment of these tumors besides having a functional outcome comparable to the healthy limb.
Keywords
argon plasma coagulation - giant cell tumor of bone - bone neoplasms - chemoradiotherapy, adjuvant - orthopedicsFinancial Support
There was no financial support from public, commercial, or non-profit sources.
Work developed at Dept of Orthopaedics, Sir Ganga Ram Hospital, New Delhi, India.
Publication History
Received: 12 June 2021
Accepted: 22 November 2021
Article published online:
15 February 2022
© 2022. Sociedade Brasileira de Ortopedia e Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referências
- 1 Sobti A, Agrawal P, Agarwala S, Agarwal M. Giant Cell Tumor of Bone - An Overview. Arch Bone Jt Surg 2016; 4 (01) 2-9
- 2 Dreinhöfer KE, Rydholm A, Bauer HC, Kreicbergs A. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases. J Bone Joint Surg Br 1995; 77 (02) 189-193
- 3 Campanacci M. Giant-cell tumor and chondrosarcomas: grading, treatment and results (studies of 209 and 131 cases). Recent Results Cancer Res 1976; (54) 257-261
- 4 Cohen J, Abedi M, Haber G. et al. Argon plasma coagulation: a new effective technique of non-contact thermal coagulation. Experience in 44 cases of GI angiomata. Gastrointest Endosc 1996; 43: 293
- 5 Schajowicz F. Giant-Cell Tumor (Osteoclastoma). In: Tumors and Tumorlike Lesions of Bone and Joints. New York: Springer; 1981: 301-367
- 6 Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol 2001; 27 (02) 200-202
- 7 Malawer MM, Bickels J, Meller I, Buch RG, Henshaw RM, Kollender Y. Cryosurgery in the treatment of giant cell tumor. A long-term followup study. Clin Orthop Relat Res 1999; (359) 176-188
- 8 McDonald DJ, Sim FH, McLeod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am 1986; 68 (02) 235-242
- 9 Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69 (01) 106-114
- 10 O'Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994; 76 (12) 1827-1833
- 11 Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 1999; 81 (06) 811-820
- 12 Turcotte RE, Wunder JS, Isler MH. et al; Canadian Sarcoma Group. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002; (397) 248-258
- 13 Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res 2004; (424) 221-226
- 14 Su YP, Chen WM, Chen TH. Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop 2004; 28 (04) 239-243
- 15 Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res 2005; (435) 211-218
- 16 Malek F, Krueger P, Hatmi ZN, Malayeri AA, Faezipour H, O'Donnell RJ. Local control of long bone giant cell tumour using curettage, burring and bone grafting without adjuvant therapy. Int Orthop 2006; 30 (06) 495-498
- 17 Lewis VO, Wei A, Mendoza T, Primus F, Peabody T, Simon MA. Argon beam coagulation as an adjuvant for local control of giant cell tumor. Clin Orthop Relat Res 2007; 454 (454) 192-197
- 18 Balke M, Schremper L, Gebert C. et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008; 134 (09) 969-978
- 19 Kivioja AH, Blomqvist C, Hietaniemi K. et al. Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 2008; 79 (01) 86-93
- 20 Errani C, Ruggieri P, Asenzio MA. et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev 2010; 36 (01) 1-7
- 21 Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 2011; 469 (02) 591-599
- 22 Benevenia J, Patterson FR, Beebe KS, Abdelshahed MM, Uglialoro AD. Comparison of phenol and argon beam coagulation as adjuvant therapies in the treatment of stage 2 and 3 benign-aggressive bone tumors. Orthopedics 2012; 35 (03) e371-e378
- 23 Wang YL, Min L, Duan H. et al. [Therapeutic Effect of Uncemented Allograft-prosthetic Composite for the Reconstruction of Tumorous Bone Defect]. Sichuan Da Xue Xue Bao Yi Xue Ban 2018; 49 (01) 129-132
- 24 Takeuchi A, Suwanpramote P, Yamamoto N. et al. Mid- to long-term clinical outcome of giant cell tumor of bone treated with calcium phosphate cement following thorough curettage and phenolization. J Surg Oncol 2018; 117 (06) 1232-1238